Global Robot-Assisted Percutaneous Coronary Intervention (PCI) Market Analysis By Type (Robot-assisted Procedures, Fully Automated Procedures), By Component (Robotic Systems, Control Consoles, Catheters and Guidewires), By Application (Coronary Angioplasty, Stent Placement, Thrombectomy), By End-Use (Hospitals, Cardiac Catheterization Laboratories, Ambulatory Surgical Centres, Others), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Global Robot-Assisted Percutaneous Coronary Intervention (PCI) Market size is expected to be worth around USD 330.9 Billion by 2033, from USD 13.7 Billion in 2023, growing at a CAGR of 37.5% during the forecast period from 2024 to 2033.

Robot-Assisted PCI is a cutting-edge, minimally invasive procedure for treating coronary artery disease. Utilizing a robotic system, physicians can navigate catheters and place stents with greater precision. This technology enhances control, reduces radiation exposure, and improves ergonomics for operators. While clinical outcomes are promising, challenges include high costs and a steep learning curve. Limited availability also restricts its widespread use. Future advancements, including AI integration, are anticipated to boost adoption and effectiveness, making Robot-Assisted PCI a significant innovation in interventional cardiology.

Robot-assisted percutaneous coronary intervention (PCI) is increasingly popular due to its precision and reduced radiation exposure for patients and medical staff. Technological advancements and the rising number of cardiovascular disease cases drive this trend. According to the American Heart Association, over 900,000 PCI procedures are performed annually in the U.S., with a growing shift towards robotic assistance. In Europe, approximately 1.5 million PCI procedures occur yearly, with an 8% annual increase in the use of robotic systems. A Swiss study found that robotic PCI is effective in complex cases, enhancing procedural safety and outcomes.

Regulatory bodies such as the FDA and the European Medicines Agency (EMA) have approved several robotic PCI systems, ensuring that they meet stringent safety and efficacy standards. The U.S. leads in the export of these systems, valued at USD 300 million in 2023, with major import markets including Europe, Japan, and China.

The global market for robot-assisted PCI is propelled by the increasing prevalence of cardiovascular diseases. The World Health Organization (WHO) estimates that approximately 17.9 million people are affected by these diseases globally. Government initiatives are also significant contributors to this growth. For instance, in 2023, the U.S. government invested USD 1.2 billion in healthcare technology to boost the adoption of robotic surgical systems.

The expansion of the robot-assisted PCI market is further supported by the increasing incidence of cardiovascular diseases, which resulted in 20.5 million deaths globally in 2021, according to the World Heart Federation. The American Heart Association also reports that cardiovascular diseases accounted for approximately 19.1 million deaths in 2020. These factors collectively drive the market for robot-assisted PCI, as advanced robotic systems offer improved precision and outcomes in cardiovascular treatments.

In the field of robotic-assisted percutaneous coronary intervention (PCI), significant developments have occurred. Corindus Vascular Robotics, a Siemens Healthineers company, introduced the CorPath GRX system, enhancing procedural precision and control. Abbott expanded its vascular product portfolio by acquiring Walk Vascular, including robotic-assisted interventions.

Medtronic partnered with CathWorks in 2023 to integrate their robotic PCI systems with diagnostic technologies. Philips signed an agreement with a leading U.S. hospital network to implement robotic PCI systems. Boston Scientific expanded its robotic-assisted PCI facilities in Asia, targeting China and India. Additionally, Intuitive Surgical merged with a European robotic technology firm to strengthen its global market presence.

Key Takeaways

• Market Size: Expected to reach USD 330.9 billion by 2033, from USD 13.7 billion in 2023, at a CAGR of 37.5%.
• Procedure Advantages: Enhances precision, reduces radiation exposure, and improves ergonomics for operators, despite high costs and a steep learning curve.
• Robot-Assisted Procedures: Dominated the market in 2023 with over 62% share, driven by technological advancements and rising cardiovascular disease prevalence.
• Robotic Systems: Held 46% market share in 2023, driven by precision, reliability, and demand for minimally invasive procedures.
• Coronary Angioplasty: Accounted for over 39% share in 2023, due to rising coronary artery diseases and adoption of minimally invasive techniques.
• North America: Dominated with 39.9% market share in 2023, valued at USD 5.5 billion, driven by advanced healthcare infrastructure and significant investments.
• Cardiovascular Diseases: WHO estimates 17.9 million deaths annually from CVDs, driving demand for advanced medical interventions like robot-assisted PCI.
• Technological Advancements: AI and machine learning integration in robotic systems enhance precision and outcomes, driving market growth.
• Collaborations: Increased partnerships between medical device manufacturers and healthcare providers advance robot-assisted technologies and procedural success rates.
• High Costs: Initial purchase price of robot-assisted PCI systems around USD 650,000, with additional costs per procedure, limits widespread adoption.

Type Analysis

In 2023, the Robot-assisted Procedures segment held a dominant market position in the Type Segment of the Robot-Assisted Percutaneous Coronary Intervention (PCI) Market, capturing more than a 62% share. This significant market share can be attributed to several factors, including the increasing adoption of robotic systems in medical procedures due to their precision and reduced risk of complications. The segment has witnessed robust growth driven by technological advancements and the rising prevalence of cardiovascular diseases, which necessitate advanced interventional procedures.

The Fully Automated Procedures segment, while still in its nascent stages, is anticipated to experience substantial growth over the forecast period. This growth is expected to be fueled by ongoing innovations in automation technologies and increasing investments in research and development. The potential benefits of fully automated systems, such as enhanced procedural efficiency and minimized human error, are projected to drive their adoption in the coming years.

The Robot-Assisted PCI market is poised for significant expansion, with both Robot-assisted and Fully Automated Procedures segments contributing to its growth. The continuous improvements in robotic technologies and the increasing acceptance among healthcare professionals are likely to sustain the market’s upward trajectory.

Component Analysis

In 2023, the Robotic Systems segment held a dominant market position in the Component segment of the Robot-Assisted Percutaneous Coronary Intervention (PCI) market, capturing more than a 46% share. This significant market share can be attributed to the increasing adoption of advanced robotic systems in healthcare facilities, driven by their precision, reliability, and the growing demand for minimally invasive surgical procedures.

The Robotic Systems segment’s dominance is further supported by continuous technological advancements, which enhance the capabilities and efficiency of these systems. Key players in this segment are heavily investing in research and development to introduce innovative features, such as improved imaging technologies and enhanced automation, which contribute to better patient outcomes and reduced procedure times.

Moreover, the increasing prevalence of cardiovascular diseases globally and the rising awareness among healthcare providers about the benefits of robotic-assisted procedures are pivotal factors boosting the demand for robotic systems. The integration of artificial intelligence and machine learning in robotic systems is expected to further drive market growth, offering improved diagnostic and therapeutic capabilities.

In addition to Robotic Systems, the market is segmented into other components, including Instrument & Accessories and Services. The Instrument & Accessories segment is projected to experience steady growth due to the recurrent need for consumables and the expansion of robotic-assisted PCI procedures. The Services segment is anticipated to grow as well, fueled by the need for regular maintenance, training, and technical support for these advanced robotic systems.

Application Analysis

In 2023, the Coronary Angioplasty segment held a dominant market position in the Application Segment of the Robot-Assisted Percutaneous Coronary Intervention (PCI) Market, capturing more than a 39% share. This significant market share can be attributed to the rising prevalence of coronary artery diseases and the increasing adoption of minimally invasive surgical techniques. Technological advancements in robotic systems have enhanced the precision and efficacy of coronary angioplasty procedures, thereby driving the demand in this segment.

The Stent Placement segment also demonstrated substantial growth, accounting for a significant portion of the market share in 2023. This expansion is primarily due to the increasing number of percutaneous coronary interventions that necessitate stent deployment to prevent restenosis and improve long-term patient outcomes. Innovations in stent technology, including drug-eluting stents and bioresorbable scaffolds, have further propelled the adoption of robot-assisted stent placement procedures.

Thrombectomy procedures, involving the removal of blood clots from coronary arteries, also held a notable market share in 2023. The rising incidence of acute coronary syndromes and the need for rapid revascularization to restore blood flow have driven the growth of this segment. The precision and control offered by robotic systems during thrombectomy procedures enhance clinical outcomes, contributing to the segment’s market presence.

End-Use Analysis

In 2023, the Hospitals segment held a dominant market position in the End-Use Segment of the Robot-Assisted Percutaneous Coronary Intervention (PCI) Market, capturing more than a 39% share. This significant market share can be attributed to the extensive adoption of advanced robotic systems in hospital settings, driven by the increasing demand for minimally invasive surgical procedures and enhanced patient outcomes. The comprehensive infrastructure, availability of skilled medical professionals, and high patient inflow further bolster the prominence of hospitals in this segment.

Cardiac Catheterization Laboratories also play a critical role in the market, contributing substantially to the overall market dynamics. These specialized facilities are equipped with advanced diagnostic and interventional tools, making them ideal for robot-assisted PCI procedures. The growing incidence of cardiovascular diseases and the consequent rise in interventional cardiology procedures have propelled the adoption of robotic systems in these laboratories.

Ambulatory Surgical Centers (ASCs) represent an emerging segment within the Robot-Assisted PCI Market. ASCs offer several advantages, including lower costs, reduced hospital stays, and improved convenience for patients. The integration of robotic systems in ASCs is gradually increasing, driven by advancements in robotic technology and the rising preference for outpatient surgical procedures.

Other end-use segments, including specialty clinics and research institutions, also contribute to the market, albeit to a lesser extent. These segments focus on innovative research and development activities, exploring new applications and efficiencies of robotic systems in PCI procedures. The collective efforts across various end-use segments underscore the expanding landscape of the Robot-Assisted PCI Market, highlighting the growing acceptance and integration of robotic technologies in cardiovascular interventions.

Key Market Segments

Type

• Robot-assisted Procedures
• Fully Automated Procedures

Component

• Robotic Systems
• Control Consoles
• Catheters and Guidewires

Application

• Coronary Angioplasty
• Stent Placement
• Thrombectomy

End-Use

• Hospitals
• Cardiac Catheterization Laboratories
• Ambulatory Surgical Centers
• Others

Drivers

Increasing Prevalence Of Cardiovascular Diseases

The increasing prevalence of cardiovascular diseases (CVDs) globally is significantly driving the robot-assisted percutaneous coronary intervention (PCI) market. According to the World Health Organization, an estimated 17.9 million people die from CVDs each year, accounting for 32% of all global deaths, with 85% of these deaths due to heart attack and stroke. This high mortality rate underscores the urgent need for advanced medical interventions.

Furthermore, as the demand for minimally invasive surgical procedures rises, the adoption of robot-assisted PCI is growing. These procedures offer precision, reduced recovery times, and improved patient outcomes, making them a preferred choice in managing CVDs. The American Heart Association also highlights the increasing incidence of coronary heart disease, further emphasizing the need for innovative treatment options like robot-assisted PCI to manage the escalating burden of cardiovascular conditions effectively​

Restraints

High Cost

The high cost associated with robot-assisted percutaneous coronary intervention (PCI) systems presents a significant restraint to market expansion. These systems, such as the CorPath GRX from Corindus, Inc., have an initial purchase price of approximately USD 650,000. Additionally, each procedure requires disposable accessories costing between USD 650 and USD 750. These substantial expenses can be prohibitive, especially for healthcare facilities in developing regions with limited budgets.

Moreover, the operation of robot-assisted PCI systems necessitates specialized cardiac catheterization labs equipped with advanced imaging technology and highly trained personnel, further elevating the overall cost. The lack of skilled cardiologists trained in robotic procedures also hinders adoption. In regions like the United States, where there is a strong healthcare infrastructure, these systems are more prevalent, yet cost remains a critical factor limiting widespread use​.

Opportunities

Technological advancements in robotic systems

Advancements in robotic-assisted Percutaneous Coronary Intervention (PCI) offer substantial opportunities for market growth, driven by technological enhancements and proven clinical efficacy. Recent studies emphasize the high success rates of robot-assisted PCI, such as one early trial reporting a clinical success rate of 100%, a technical success rate of 94%, and an overall surgical success rate of 83%. Another pivotal study, the PRECISE trial, demonstrated a technical success rate of 97.9% with the robotic system, while significantly reducing radiation exposure to the operator by over 95%​.

These advancements and the encouraging results from clinical trials highlight the potential for robot-assisted PCI to become more prevalent, offering a safer and more effective alternative to traditional methods, particularly in complex cardiac interventions

Trends

Increasing Collaboration Between Medical Device Manufacturers And Healthcare Providers

The increasing integration of robotics in Percutaneous Coronary Intervention (PCI) is a significant trend in the market, driven by collaborations between medical device manufacturers and healthcare providers. This cooperation is aimed at advancing the development and implementation of robot-assisted technologies in PCI procedures, thereby improving success rates and encouraging broader adoption.

From a data perspective, studies have highlighted the efficiency and safety of robotic-assisted PCI. For instance, the PRECISE study observed a technical success rate of 98.8% in robotic-assisted procedures without any adverse events like death or stroke within a 30-day follow-up period. This study underscored the potential for robotic systems to significantly reduce the median radiation exposure for operators, a critical benefit given the occupational hazards in interventional cardiology​.

Moreover, a study on the feasibility of robotic-assisted PCI for complex lesions found that although the total procedure time was slightly longer, there were no significant differences in contrast volume or patient radiation exposure compared to manual procedures. This suggests that robotic-assisted PCI can handle complex cases effectively, aligning with trends towards minimizing invasive procedures and enhancing patient safety.

This trend towards robotic-assisted PCI not only enhances procedural accuracy and safety but also positions healthcare facilities at the forefront of technological adoption, attracting both patients and skilled healthcare professionals. The collaborations between key industry players and healthcare providers are pivotal in driving forward these advancements, ensuring the technology’s integration into regular clinical practice.

Regional Analysis

In 2023, North America held a dominant market position in the Robot-Assisted Percutaneous Coronary Intervention (PCI) market, capturing more than a 39.9% share and holding a market value of USD 5.5 billion for the year. This prominence can be attributed to the region’s advanced healthcare infrastructure, high adoption rates of cutting-edge medical technologies, and substantial investments in robotic surgery systems. Furthermore, the presence of leading robotics and medical device companies in this region fuels innovation and accessibility to robot-assisted PCI solutions.

In contrast, Europe followed closely, propelled by supportive government policies that facilitate healthcare innovation and robust funding mechanisms for healthcare facilities seeking technological upgrades. The market in Europe is expected to experience significant growth, driven by increasing cardiac disease prevalence and rising demand for minimally invasive procedures.

Asia-Pacific presents a rapidly expanding market for robot-assisted PCI, driven by increasing healthcare expenditures and growing awareness of advanced therapeutic options among healthcare providers and patients. Countries like China, Japan, and South Korea are investing heavily in healthcare infrastructure development and adopting new technologies at a swift pace, which is likely to boost the market growth in this region.

Latin America and the Middle East & Africa regions are emerging markets with potential growth in the robot-assisted PCI sector. These regions are experiencing gradual growth due to increasing healthcare reforms, rising economic stability, and the slow yet steady adoption of advanced medical technologies. The market in these areas is expected to grow as healthcare systems continue to evolve and as there is an increasing presence of global players expanding their reach into these markets.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

Siemens Healthineers, Hansen Medical, Robocath, Catheter Precision, and other key players are driving significant advancements in the robot-assisted Percutaneous Coronary Intervention (PCI) market. Siemens Healthineers is noted for its cutting-edge medical imaging and diagnostics technologies, which enhance the precision and efficiency of cardiac interventions. Meanwhile, Hansen Medical specializes in intravascular robotics, offering systems that improve the accuracy of catheter navigation in complex coronary procedures.

Robocath contributes with robotic systems designed to ensure stability and precision during cardiac interventions, aiming to reduce physician fatigue and enhance procedural accuracy. On the other hand, Catheter Precision develops advanced mapping systems that aid in the precise application of catheter-based treatments, increasing the safety and success rates of interventions. Collectively, these companies are integral to the evolution of interventional cardiology, pushing the boundaries of medical technology to improve clinical outcomes and patient care.

Market Key Players

• Siemens Healthineers
• Hansen Medical
• Robocath
• Catheter Precision
• Medtronic plc
• BOSTON SCIENTIFIC CORPORATION
• Intuitive Surgical Inc.
• Stereotaxis Inc.
• Siemens Healthineers
• Hocoma AG
• Clear Surgical Inc.

Recent Developments

• In January 2024, Stereotaxis Inc. secured FDA clearance for its redesigned Genesis RMN System, which is used for robotic navigation of magnetic ablation catheters to treat heart rhythm disorders. This development marked a significant milestone, enabling the commercialization of the Genesis RMN System in the U.S., thereby expanding its market presence​.
• In May 2023, Siemens Healthineers announced the discontinuation of the CorPath GRX robotic system due to disappointing sales. This decision impacted hospitals relying on this technology, such as the program at a major hospital which faced operational challenges due to the unavailability of single-use cassettes required for the system.
• In February 2022, Robocath’s R-One robotic system received significant attention after its CE marking approval. The system is now available throughout Europe and Africa, enhancing the reach of robotic-assisted PCI in these regions. This expansion has positioned Robocath as a key player in the European and African markets for robotic PCI systems​.
• In March 2022, Medtronic plc launched a new robotic-assisted PCI system designed to enhance procedural efficiency and precision. This new system integrates advanced imaging technologies and automation to improve outcomes in complex PCI procedures. The launch is part of Medtronic’s strategy to strengthen its position in the robotic-assisted intervention market.

Report Scope